Table 1.

Recent complement mediating therapeutics directed against AMD in clinical trials

Therapeutic (alt. name)a	Drug class	Delivery method	Complement target	Company	AMD form targeted	Clinical trial
APL-2	Peptide	Monthly intravitreal injection	C3	Apellis	Dry	NCT03525600 NCT03525613 Phase III
Zimura (ARC1905)	Aptamer-based inhibitor	Monthly intravitreal injection	C5	IVERIC bio	Dry	NCT04435366 Phase III
					Wet	NCT03362190 Phase II
IONIS-FB-LRx	siRNA	Subcutaneous injection	FB	Ionis Pharmaceuticals	Dry	NCT03815825 Phase II
GEM103	Biologic	Monthly intravitreal injection	FH	Gemini Therapeutics	Dry	NCT04246866 Phase I
GT005	AAV gene therapy	Single sub-retinal injection	FI	Gyroscope Therapeutics	Dry	NCT03846193 NCT04437368 Phase I
AAVCAGsCD CD59	AAV gene therapy	Single sub-retinal injection	CD59	Hemera Biosciences	Dry	NCT03144999 Phase I
Recently terminated trials
Lampalizumab (FCD4514S)	Antibody Fab fragment	Monthly intravitreal injection	Factor D	Genentech/Roche	Dry	NCT02247479 NCT02247531 Phase III Terminated
CLG561 (in combination with LFG316)	Monoclonal antibody	Monthly intravitreal injection	Properdin	Alcon/Novartis	Dry	NCT02515942 Phase II Terminated

^aIn some instances, the therapeutics listed have been known previously by a different name